0001193125-20-215626.txt : 20200811 0001193125-20-215626.hdr.sgml : 20200811 20200811073054 ACCESSION NUMBER: 0001193125-20-215626 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20200807 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20200811 DATE AS OF CHANGE: 20200811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001660334 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463137900 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38529 FILM NUMBER: 201091058 BUSINESS ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-453-3300 MAIL ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 8-K 1 d65032d8k.htm FORM 8-K Form 8-K
false 0001660334 0001660334 2020-08-07 2020-08-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2020

 

 

Verrica Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-38529   46-3137900

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

10 North High Street, Suite 200

West Chester, PA

   19380
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (484) 453-3300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

  

Trading

symbol

  

Name of each exchange

on which registered

Common Stock   VRCA   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 1.01

Entry into a Material Definitive Agreement

On August 7, 2020, Verrica Pharmaceuticals Inc., or the Company, entered into an exclusive license agreement, or the Lytix Agreement, with Lytix Biopharma AS, or Lytix, pursuant to which the Company obtained a worldwide, exclusive, royalty-bearing license, with the right to sublicense, for certain technology of Lytix to research, develop, manufacture, have manufactured, use, sell, have sold, offer for sale, import and otherwise commercialize LTX-315 for use in all malignant and pre-malignant dermatological indications, other than metastatic melanoma and metastatic merkel cell carcinoma. The Company’s right to manufacture the active pharmaceutical ingredient is limited to certain instances, and Lytix is obligated to manufacture and supply the Company’s clinical and commercial needs for such active pharmaceutical ingredient. The Company is obligated to use commercially reasonable efforts to develop and to commercialize the product, which development and commercialization will be overseen by a joint steering committee. Lytix has agreed not to pursue any products in the field of dermatology other than LTX-315 for use in metastatic melanoma and metastatic merkel cell carcinoma. Lytix has granted the Company an exclusive option to negotiate for an exclusive license for use of LTX-315 in additional dermatological indications.

In connection with entering the Lytix Agreement, the Company agreed to make an initial payment of $250,000. Additionally, the Company is obligated to pay a near term regulatory milestone payment of $2.25 million, up to $111.0 million contingent on achievement of specified development, regulatory, and sales milestones, and tiered royalties based on worldwide annual net sales ranging in the low double digits to the mid-teens, subject to certain customary reductions. The Company’s obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of the expiration or abandonment of the last to expire licensed patent covering LTX-315 anywhere in the world and expiration of regulatory exclusivity for LTX-315 in such country. Additionally, all upfront fees and milestone based payments received by the Company from a sublicensee will be treated as net sales and will be subject to the royalty payment obligations under the Lytix Agreement, and all royalties received by the Company from a sublicensee shall be shared with Lytix at a rate that is initially 50% but decreases based on the stage of development of LTX-315 at the time such sublicense is granted.

The Lytix Agreement expires on a product-by-product and a country-by-country basis upon expiration of the royalty term for such product in such country. At any time after the first anniversary of the execution of the Lytix Agreement, the Company has the right to terminate the agreement, either on a region-by-region basis or in its entirety, upon specified written notice to Lytix. Lytix may terminate the agreement, either on a region-by-region basis or in its entirety, if the Company develops or commercializes a competing product in the licensed field, or in its entirety if the Company challenges the validity, enforceability or scope of any licensed patent, subject in each case to certain cure rights. Either party may terminate the Lytix Agreement in the event of an uncured material breach or insolvency of the other party.

The foregoing is a summary description of certain terms of the Lytix Agreement, is not complete and is qualified in its entirety by reference to the text of the Lytix Agreement, which the Company expects to file as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Verrica Pharmaceuticals Inc.
Date: August 11, 2020      

/s/ A. Brian Davis

      A. Brian Davis
      Chief Financial Officer
 EX-101.SCH 2 vrca-20200807.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 vrca-20200807_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 vrca-20200807_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d65032d8k_htm.xml IDEA: XBRL DOCUMENT 0001660334 2020-08-07 2020-08-07 false 0001660334 8-K 2020-08-07 Verrica Pharmaceuticals Inc. DE 001-38529 46-3137900 10 North High Street Suite 200 West Chester PA 19380 (484) 453-3300 false false false false Common Stock VRCA NASDAQ true true XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Aug. 07, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001660334
Document Type 8-K
Document Period End Date Aug. 07, 2020
Entity Registrant Name Verrica Pharmaceuticals Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38529
Entity Tax Identification Number 46-3137900
Entity Address, Address Line One 10 North High Street
Entity Address, Address Line Two Suite 200
Entity Address, City or Town West Chester
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19380
City Area Code (484)
Local Phone Number 453-3300
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol VRCA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d65032d8k.htm vrca-20200807.xsd vrca-20200807_lab.xml vrca-20200807_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d65032d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d65032d8k.htm" ] }, "labelLink": { "local": [ "vrca-20200807_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "vrca-20200807_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "vrca-20200807.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vrca", "nsuri": "http://www.verrica.com/20200807", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d65032d8k.htm", "contextRef": "duration_2020-08-07_to_2020-08-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d65032d8k.htm", "contextRef": "duration_2020-08-07_to_2020-08-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.verrica.com//20200807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-20-215626-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-215626-xbrl.zip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end